Is Valeant’s Big Offer for Allergan Big Enough?

Or is Valeant set to offer even more?

The Motley Fool

On April 22, 2014, Valeant Pharmaceuticals (TSX: VRX)(NYSE: VRX) made an unsolicited offer of around $46 billion to the shareholders of Allergan (NYSE: AGN), a top-tier pharmaceutical company. The cash and share offer, which amounted to around $154 per Allergan share, represented a substantial premium compared to the $115-$125 price prevailing in the weeks before the offer was made.

After the Allergan board’s rejection of the initial offer, the Valeant board improved the offer further on two occasions. On May 28, 2014, the cash component of the offer was increased to $58.30 per share from $48.30 per share, and again to $73 per share two days later. The 0.83 share exchange ratio remained unchanged but Valeant also included a contingent value right linked to future sales of a drug that is still under development.

Based on the current share price of Valeant, the offer is worth around $183 per Allergan share, excluding the speculative component of the contingent value right. The offer values Allergan at a 2014 EV/EBITDA ratio of 21 times; this is considerably higher than the valuation of a representative peer group, which trades on an estimated multiple of 12 times. Based on Valeant’s calculation of $2.7 billion in savings through a business combination, the offer multiple could drop to an estimated 14.5 times, which would still represent a considerable premium to the peer group valuation.

Will Valeant increase the offer a third time?

The offer on the table is, in my view, already a full price for Allergan. In addition, Valeant has limited options to further increase the cash component of the offer given its already stretched balance sheet and limitations on the issue of additional shares. Apart from marginal tweaking, it is therefore unlikely that the offer will be further materially improved.

What will Allergan’s shareholders do?

Apart from the two bidding parties (Valeant and Pershing Square, which combined hold 9.7% of Allergan’s shares), the other shareholders are mainly investment funds. Although this battle may continue for much longer with interesting twists and turns, one could imagine that these shareholders would look to optimize the windfall profit brought about by the Valeant offer.

Given the rich offer already on the table, the considerable execution risks to Allergan’s shareholders, and perceptions of an inflated Valeant share price and unsustainable business model, current Allergan shareholders may be tempted to sell their stock in the market to lock in the considerable gains they have already experienced.

Fool contributor Deon Vernooy does not hold a position in any company mentioned above.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »